Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2025-12-25 @ 8:43 PM
Study NCT ID:
NCT05579366
Status:
RECRUITING
Last Update Posted:
2025-12-05
First Post:
2022-10-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005185', 'term': 'Fallopian Tube Neoplasms'}, {'id': 'D016889', 'term': 'Endometrial Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D008654', 'term': 'Mesothelioma'}, {'id': 'D064726', 'term': 'Triple Negative Breast Neoplasms'}, {'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D010051', 'term': 'Ovarian Neoplasms'}, {'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005184', 'term': 'Fallopian Tube Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D000236', 'term': 'Adenoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D018301', 'term': 'Neoplasms, Mesothelial'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'C582435', 'term': 'pembrolizumab'}], 'ancestors': [{'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 764}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-12-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-01', 'studyFirstSubmitDate': '2022-10-04', 'studyFirstSubmitQcDate': '2022-10-11', 'lastUpdatePostDateStruct': {'date': '2025-12-05', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-10-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]', 'timeFrame': 'Through end of treatment, up to approximately 1 year.'}, {'measure': 'Parts A, and D - Dose Limiting Toxicity (DLT)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 21 days)', 'description': 'The proportion of participants experiencing DLT.'}, {'measure': 'Parts C, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C, E, and F) or Investigator (Part G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'timeFrame': 'Through end of treatment, up to approximately 1 year.', 'description': 'Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.'}, {'measure': 'Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by Holter', 'timeFrame': 'Cycles 1 to 3 (each cycle is 21 days)'}], 'secondaryOutcomes': [{'measure': 'Parts A, B, and D - Best Overall Response (BOR)', 'timeFrame': 'Up to approximately 1 year.', 'description': 'Participants who achieve CR or PR. Best response as assessed by the investigator per RECIST v1.1 criteria for all tumor types other than pleural mesothelioma which will use modified RECIST (mRECIST) v1.1.'}, {'measure': 'Parts A, B, and D - ORR', 'timeFrame': 'Up to approximately 1 year.', 'description': 'Participants who achieve PR or CR per RECIST v1.1 criteria.'}, {'measure': 'Parts A, B, and D - Disease Control Rate (DCR)', 'timeFrame': 'Up to approximately 1 year.', 'description': 'Participants who achieve stable disease, PR or CR per RECIST v1.1 criteria.'}, {'measure': 'Parts A, B, C, D, F, G, H, I, and J - Progression-Free Survival (PFS)', 'timeFrame': 'Through end of treatment, up to approximately 1 year.', 'description': 'Time from start of treatment to first documented disease progression or death'}, {'measure': 'Parts C, F, G, H, I and J - Overall survival (OS)', 'timeFrame': 'Up to approximately 2 years.', 'description': 'Time from the start of study treatment to the date of death from any cause'}, {'measure': 'Parts A, B, C, D, F, H, I and J - Duration of Objective Response (DOR)', 'timeFrame': 'From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.', 'description': 'Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death'}, {'measure': 'Parts A, B, and D - Peak Plasma Concentration (Cmax) for Rina-S', 'timeFrame': 'Through end of treatment, up to approximately 1 year.', 'description': 'Measurement of maximum plasma concentration after the administration of Rina-S.'}, {'measure': 'Parts A, B, and D - Area Under the Plasma Concentration Versus Time Curve (AUC) for Rina-S', 'timeFrame': 'Through end of treatment, up to approximately 1 year.', 'description': 'Measurement of AUC after the administration of Rina-S.'}, {'measure': 'Parts A, B, and D -Time to Reach Cmax (Tmax) for Rina-S', 'timeFrame': 'Through end of treatment, up to approximately 1 year'}, {'measure': 'Parts A, B, and D - Trough Concentrations (Ctrough) for Rina-S', 'timeFrame': 'Through end of treatment, up to approximately 1 year'}, {'measure': 'Parts A, B, and D - Apparent Terminal Half-life (t1/2) for Rina-S', 'timeFrame': 'Through end of treatment, up to approximately 1 year'}, {'measure': 'Parts C, D, H and J - CA-125 Response Determined Using the Gynecologic Cancer Intergroup (GCIG) Criteria', 'timeFrame': 'Through end of treatment, up to approximately 1 year'}, {'measure': 'Parts C, F, H, I, J, and K - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)', 'timeFrame': 'Through end of treatment, up to approximately 1 year'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['antibody-drug conjugate', 'folate receptor alpha', 'folate receptor', 'solid tumor', 'ovarian cancer', 'primary peritoneal carcinoma', 'fallopian tube cancer', 'endometrial cancer', 'non-small cell lung cancer', 'mesothelioma', 'breast cancer', 'triple negative breast cancer', 'hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer', 'topoisomerase I inhibitor', 'PROC', 'epidermal growth factor receptor (EGFR)-mutated NSCLC'], 'conditions': ['High Grade Epithelial Ovarian Cancer', 'High Grade Serous Ovarian Cancer', 'Primary Peritoneal Carcinoma', 'Fallopian Tube Cancer', 'Endometrial Cancer', 'Non-small Cell Lung Cancer', 'Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)', 'Mesothelioma', 'Breast Adenocarcinoma', 'Triple Negative Breast Cancer', 'Hormone Receptor-positive/Her2 Negative Breast Cancer', 'Platinum-resistant Ovarian Cancer (PROC)', 'Platinum Sensitive Ovarian Cancer (PSOC)', 'Primary Refractory Ovarian Cancer', 'Uterine Cancer']}, 'descriptionModule': {'briefSummary': 'This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.\n\nParticipants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).', 'detailedDescription': 'This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.\n\nThe study consists of multiple parts:\n\nPart A: monotherapy cohorts\n\nPart B: tumor-specific monotherapy dose-expansion cohorts\n\nPart C: platinum-resistant ovarian cancer (PROC) monotherapy cohort\n\nPart D: combination therapy cohorts\n\nParts F and G: a monotherapy endometrial cancer (EC) cohort\n\nPart H: a monotherapy PROC cohort\n\nPart I: platinum-sensitive ovarian cancer (PSOC) cohort\n\nPart J: a monotherapy PROC cohort\n\nPart K: a monotherapy high-grade ovarian cancer cohort\n\nParticipants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nPart A and B:\n\n* Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).\n* Previously received therapies known to confer clinical benefit.\n* Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.\n\nPart C and H:\n\nParticipants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.\n\n* High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)\n* Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.\n* Participants must have platinum-resistant ovarian cancer.\n* Participants must have received prior bevacizumab or approved biosimilar.\n* Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration \\[FDA\\]-approved test in a Clinical Laboratory Improvement Amendments \\[CLIA\\]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.\n* Measurable disease per the RECIST v1.1 at baseline.\n\nPart D:\n\nCohort D1:\n\n* Participants must have platinum-sensitive ovarian cancer.\n* Participants must have received 1 to 3 prior lines of therapy.\n\nCohort D2:\n\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.\n* Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.\n\n * Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (\\>183 days) or more from the last dose of platinum-based therapy.\n\nCohort D3 and D4:\n\n• Endometrial cancer (any subtype excluding sarcoma).\n\nPart F and G:\n\n* Participants must have histologically or cytologically confirmed EC.\n* Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.\n* Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:\n* Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-\\[L\\])1 inhibitor.\n* Participants who progress \\>12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.\n* Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart I:\n\n* Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade/borderline ovarian tumors).\n* Participants must have platinum sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart J:\n\n* Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart K:\n\n* Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nExclusion Criteria:\n\n* History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.\n\nNote: Other protocol-defined inclusion/exclusion may apply.'}, 'identificationModule': {'nctId': 'NCT05579366', 'acronym': 'RAINFOL-01', 'briefTitle': 'Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Genmab'}, 'officialTitle': 'Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors', 'orgStudyIdInfo': {'id': 'GCT1184-01'}, 'secondaryIdInfos': [{'id': 'CTR20230813', 'type': 'REGISTRY', 'domain': 'Chinadrugtrials.org.cn'}, {'id': 'PRO1184-001', 'type': 'OTHER', 'domain': 'Other Sponsor Identifier'}, {'id': 'jRCT2051250094', 'type': 'REGISTRY', 'domain': 'jRCT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A, B, C, F, G, H, I, J and K', 'description': 'Rina-S monotherapy in Part A and at the recommended dose in Parts B, C, F, G, H, I, J and K.', 'interventionNames': ['Drug: Rina-S']}, {'type': 'EXPERIMENTAL', 'label': 'Part D1', 'description': 'Rina-S in combination with carboplatin', 'interventionNames': ['Drug: Rina-S', 'Drug: Carboplatin']}, {'type': 'EXPERIMENTAL', 'label': 'Part D2 and I', 'description': 'Rina-S in combination with bevacizumab', 'interventionNames': ['Drug: Rina-S', 'Drug: Bevacizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part D3 and D4', 'description': 'Rina-S in combination with pembrolizumab', 'interventionNames': ['Drug: Rina-S', 'Drug: Pembrolizumab']}], 'interventions': [{'name': 'Rina-S', 'type': 'DRUG', 'otherNames': ['PRO1184', 'Rinatabart sesutecan', 'GEN1184'], 'description': 'Intravenous infusion of Rina-S', 'armGroupLabels': ['Part A, B, C, F, G, H, I, J and K', 'Part D1', 'Part D2 and I', 'Part D3 and D4']}, {'name': 'Carboplatin', 'type': 'DRUG', 'description': 'Carboplatin intravenous infusion', 'armGroupLabels': ['Part D1']}, {'name': 'Bevacizumab', 'type': 'DRUG', 'description': 'Bevacizumab intravenous infusion', 'armGroupLabels': ['Part D2 and I']}, {'name': 'Pembrolizumab', 'type': 'DRUG', 'description': 'Pembrolizumab intravenous infusion', 'armGroupLabels': ['Part D3 and D4']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85016', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR HonorHealth', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85711', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Arizona Oncology Associates', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California Los Angeles Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92093', 'city': 'San Diego', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of California, San Diego; Moores Cancer Center', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '93105', 'city': 'Santa Barbara', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Sansum Clinic', 'geoPoint': {'lat': 34.42083, 'lon': -119.69819}}, {'zip': '95403', 'city': 'Santa Rosa', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Providence Medical Foundation', 'geoPoint': {'lat': 38.44047, 'lon': -122.71443}}, {'zip': '33908', 'city': 'Fort Myers', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Florida Cancer Specialists South', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '33709', 'city': 'St. Petersburg', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Florida Cancer Specialists North', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '33401', 'city': 'West Palm Beach', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Florida Cancer Specialists East', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '66205', 'city': 'Westwood', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Kansas Medical Center (KUMC)', 'geoPoint': {'lat': 39.04056, 'lon': -94.6169}}, {'zip': '20850', 'city': 'Rockville', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Maryland Oncology Hematology', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Dana Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48085', 'city': 'Detroit', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Karmanos Cancer Institute', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'START Midwest', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '55109', 'city': 'Maplewood', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Minnesota Oncology Hematology', 'geoPoint': {'lat': 44.95302, 'lon': -92.99522}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Oklahoma - Health Sciences Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97401', 'city': 'Eugene', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Oncology Associates of Oregon, P.C.', 'geoPoint': {'lat': 44.05207, 'lon': -123.08675}}, {'zip': '97227', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Compass Oncology - Rose Quarter', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '18901', 'city': 'Doylestown', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Alliance Cancer Specialist', 'geoPoint': {'lat': 40.31011, 'lon': -75.12989}}, {'zip': '02905', 'city': 'Providence', 'state': 'Rhode Island', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Women and Infants Hospital of Rhode Island', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Sarah Cannon Research Institute at Tennessee Oncology', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Tennessee Oncology', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '79606', 'city': 'Abilene', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Texas Oncology', 'geoPoint': {'lat': 32.44874, 'lon': -99.73314}}, {'zip': '78758', 'city': 'Austin', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Texas Oncology - Central / South Texas', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75521', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Mary Crowley Cancer Research', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '76104', 'city': 'Fort Worth', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Texas Oncology', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'zip': '75702', 'city': 'Tyler', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Texas Oncology - Northeast TX', 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}}, {'zip': '77380', 'city': 'Woodland', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Texas Oncology Gulf Coast', 'geoPoint': {'lat': 31.13129, 'lon': -97.48946}}, {'zip': '84119', 'city': 'West Valley City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'START Mountain Region', 'geoPoint': {'lat': 40.69161, 'lon': -112.00105}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Virginia Cancer Specialists', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '23502', 'city': 'Norfolk', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USOR Virginia Oncology Associates', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '98104', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Swedish Cancer Institute', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Cancer hospital, Chinese Academy of Medical Sciences', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Hunan Cancer Hospital - Phase 1', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Hunan Cancer Hospital - Thoracic Medicine Dept II', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Jiangxi Maternal and Child Health Hospital', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'city': 'Changchun', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Jilin Cancer Hospital', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Fudan University Shanghai Cancer Center - Gynecologic Oncology', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Fudan University Shanghai Cancer Center- Phase 1', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Shanghai East Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Fukushima', 'state': 'Fukushima', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Fukushima Medical University Hospital', 'geoPoint': {'lat': 37.75, 'lon': 140.46667}}, {'city': 'Ōta', 'state': 'Gunma', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Gunma Prefectural Cancer Center', 'geoPoint': {'lat': 36.3, 'lon': 139.36667}}, {'city': 'Sapporo', 'state': 'Hokkaido', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Sapporo Medical University Hospital', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Akashi', 'state': 'Hyōgo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Hyogo Cancer Center', 'geoPoint': {'lat': 34.65524, 'lon': 135.00687}}, {'city': 'Hidaki-Shi', 'state': 'Saitama', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Saitama Medical University-International Medical Center'}, {'city': 'Sunto-gun', 'state': 'Shizuoka', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Shizuoka Cancer Center'}, {'city': 'Koto', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Cancer Institute Hospital of JFCR'}, {'city': 'Shinjuku-ku', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Keio University Hospital'}, {'city': 'Yamagata', 'state': 'Yamagata', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Yamagata University Hospital', 'geoPoint': {'lat': 38.23333, 'lon': 140.36667}}, {'city': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'National Cancer Center Hospital', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}], 'centralContacts': [{'name': 'Genmab Trial Information', 'role': 'CONTACT', 'email': 'clinicaltrials@genmab.com', 'phone': '+4570202728'}], 'overallOfficials': [{'name': 'Study Official', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Genmab'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Genmab', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}